Population Pharmacokinetics of Mivavotinib (TAK‐659), a Dual Spleen Tyrosine Kinase and FMS‐Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic Malignancies

• Published in: Journal of clinical pharmacology Vol. 63; no. 3; pp. 326 - 337
• Main Authors: Li, Cheryl, Watson, Kenny, Wang, Shining, Diderichsen, Paul Matthias, Gupta, Neeraj
• Format: Journal Article
• Language: English
• Published: England 01.03.2023
• Subjects: acute myeloid leukemia; Adult; Antineoplastic Agents - pharmacokinetics; FMS‐like tyrosine kinase 3; Hematologic Neoplasms - drug therapy; Humans; Leukemia, Myeloid, Acute - drug therapy; lymphoma; mivavotinib (TAK‐659); pharmacokinetics; Protein Kinase Inhibitors - pharmacokinetics; spleen tyrosine kinase; Syk Kinase; pharmacokinetics; FMS-like tyrosine kinase 3; acute myeloid leukemia; mivavotinib (TAK-659); spleen tyrosine kinase; lymphoma
• ISSN: 0091-2700; 1552-4604
• DOI: 10.1002/jcph.2174

Mivavotinib (TAK‐659), an orally administered, small‐molecule, dual inhibitor of spleen tyrosine kinase and FMS‐like tyrosine kinase 3 (SYK/FLT3), is under development for the treatment of patients with advanced malignancies. In this analysis, we evaluated the population pharmacokinetics (PK) of mivavotinib and its sources of variability (covariates) in adult patients with advanced solid tumors, or relapsed/refractory B‐cell lymphomas or acute myeloid leukemia, using pooled data from 159 patients enrolled in 2 phase 1/2 clinical studies. A 2‐compartment model with first‐order linear elimination and a first‐order absorption rate (and associated lag time) adequately described the PK of mivavotinib in this patient population. The population estimates of apparent clearance (CL/F) and apparent central compartment volume (Vc/F) were 31.6 L/h and 893 L, respectively, resulting in a half‐life of ≈20 hours. In the final model, creatinine clearance was included as a covariate of CL/F, and sex as a covariate of Vc/F. Simulations showed that steady‐state exposure to mivavotinib increased with decreasing renal function. Expanding eligibility by enrolling patients with moderate renal impairment in phase 1 increased the diversity of patients in early trials and allowed the model to inform dose adjustment in patients with moderate renal impairment in future trials. In addition, simulations showed median steady‐state trough concentration of mivavotinib following 70 mg twice daily and 160 mg daily dosing to be commensurate with 100 ng/mL, the level leading to >90% FLT3 inhibition per ex vivo plasma immune assays and considered a potential exposure threshold required for FLT3‐driven efficacy.